Unionmeditech: LH-1801 project cannot obtain market approval in the short term.

Sina Finance News on March 30th, the announcement of abnormal fluctuations in Lianhuan Pharmaceutical's stock trading. The company has noticed relevant information in the market regarding the LH-1801 project. The LH-1801 project cannot obtain listing approval in the short term, and there is significant uncertainty as to whether it can obtain listing approval and the specific time of listing approval if obtained. LH-1801 is an SGLT-2 inhibitor for treating diabetes. Currently, there are around 8 products in the market for treating type 2 diabetes. Even if LH-1801 is successfully listed in the future, it will face significant competition. Investors are advised to pay attention to the risks of secondary market trading, make rational decisions, and invest cautiously.